-
Mashup Score: 0Disease-Modifying Therapies in Progressive Multiple Sclerosis - 2 year(s) ago
Key presentations at CMSC 2022 included use of BTK inhibitors in MS, results from the DISCOMS trial, and immune response of MS patients vaccinated for COVID-19, as reported by Dr Robert Shin.
Source: www.mdedge.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 1COVID vaccination in DMT-treated MS patients: New data - 2 year(s) ago
Antibody responses were assessed in patients under treatment.
Source: www.mdedge.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 2Risk of drug interactions is on the rise as MS drugs evolve - 2 year(s) ago
Newer medications pose more danger, pharmacist says, and require more awareness.
Source: www.mdedge.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0Consider the wider picture in relapsing remitting MS - 2 year(s) ago
The best medication for a patient may not have highest efficacy, one expert says.
Source: www.mdedge.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 1Risk of Drug Interactions on the Rise as MS Treatments Evolve - 2 year(s) ago
In a new study of more than 600 patients with multiple sclerosis, about 1 in 25 faced a potentially severe drug-drug interaction, with more having at least one potentially risky interaction.
Source: MedscapeCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0Risk of drug interactions is on the rise as MS drugs evolve - 2 year(s) ago
Newer medications pose more danger, pharmacist says, and require more awareness.
Source: www.mdedge.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Novel Drug Safe, Effective in Relapsing MS: 2-Year Data - 2 year(s) ago
The investigational evobrutinib, an Bruton’s tyrosine kinase inhibitor, showed favorable safety and efficacy in the longest trial to date of a drug in this class in patients with multiple sclerosis.
Source: MedscapeCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0
Costly procedures help some patients but where to draw the line is unclear.
Source: www.mdedge.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0Inebilizumab Beneficial Across Genotypes in NMOSD - 2 year(s) ago
Inebilizumab is effective for neuromyelitis optica spectrum disorder, even among patients who are genetically at risk for reduced response to anti-CD20 therapies, new research suggests.
Source: MedscapeCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0Non-White subjects are sparse in DMT trials for MS - 2 year(s) ago
Black people only made up 1.9% of participants in studies reporting full racial data over 25 years.
Source: www.mdedge.comCategories: Latest Headlines, NeurologyTweet
Dr Robert Shin, from @MedStarGUH, highlights key presentations in DMT for MS presented at #CMSC2022. https://t.co/KaG5Vg3fPA https://t.co/1aViX7xP2I